Advertisement

Topics

Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal

07:30 EDT 2 Oct 2017 | Xconomy

Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it says is ready for Phase 3 clinical trials. West Lafayette, IN-based Endocyte (NASDAQ: ECYT) says it paid $12 million up front to German biochemicals company ABX […]

Original Article: Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal

NEXT ARTICLE

More From BioPortfolio on "Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...